Abpro Holdings, Inc.

Abpro Holdings, Inc. (Nasdaq: ACAB) is a clinical-stage biopharmaceutical company focused on bispecific antibody engineering that reached public markets through a special purpose acquisition company transaction. The company filed an 8-K current report with the Securities and Exchange Commission on September 4, 2024, disclosing a material corporate development in its post-combination phase. Abpro's proprietary antibody platform targets oncology and other therapeutic indications, placing it squarely within the life sciences SPAC cohort that defined a significant portion of the 2021–2023 deal landscape. The company operates in the biotechnology and drug discovery sector following the close of its de-SPAC transaction. For complete filing history, sponsor details, and post-merger tracking on Abpro Holdings and hundreds of other SPAC transactions, sign up for full data access at SpacDesk.